SLC39A8¹¹ SLC39A8
Also known as ZIP8 (Ziv-Irt-like Protein 8) encodes a membrane transporter that moves divalent metal ions — particularly manganese, zinc, and iron — from outside the cell into the cytoplasm.

The protein acts as a transporter for multiple metal ions including Zn²⁺, Cd²⁺, Fe²⁺, Mn²⁺, Hg²⁺, and Co²⁺ . The A391T variant (rs13107325) is one of the most pleiotropic genetic variants identified by genome-wide association studies, meaning it influences multiple, seemingly unrelated traits across different body systems.

The Mechanism

The A391T substitution replaces alanine with threonine at position 391²² replaces alanine with threonine at position 391
A more polar amino acid in the protein structure.

While the intrinsic transport properties remain similar to wild-type ZIP8, cellular uptake of zinc, cadmium, and iron is significantly reduced due to decreased ZIP8 plasma membrane expression . The variant protein simply doesn't reach the cell surface as efficiently, limiting the amount of metal ions that can be transported into cells.

This has particularly important consequences in the intestinal epithelium.

Intestinal epithelial SLC39A8 controls intestinal manganese absorption and epithelial integrity . When ZIP8 function is impaired, manganese becomes less available to intestinal cells³³ manganese becomes less available to intestinal cells
Mn is essential for glycosyltransferase enzymes, which build the protective glycocalyx layer and mucus that form the gut barrier.

The Evidence

The strongest association is with Crohn's disease⁴⁴ Crohn's disease
A form of inflammatory bowel disease.

In an exome-wide study of 10,523 IBD cases and 5,726 controls, the A391T variant was significantly associated with Crohn's disease (combined meta-analysis p=5.55×10⁻¹³, OR=1.31) . The T allele (threonine) is the risk variant.

More strikingly, the Crohn's disease risk allele was associated with altered colonic microbiome composition in both healthy controls (p=0.009) and Crohn's disease cases (p=0.0009), with microbes depleted in healthy carriers strongly overlapping with those reduced in CD patients (p=9.24×10⁻¹⁶) and overweight individuals (p=6.73×10⁻¹⁶) . This suggests the variant affects the gut ecosystem even before disease develops.

Mouse studies confirm the mechanism.

A393T knockin mice (corresponding to human A391T) showed reduced levels of multiple divalent metals — including manganese, zinc, iron, cobalt, and cadmium — in the colonic lumen, with manganese being most significantly affected due to its role in glycosyltransferase enzymes that build the gut barrier.

The variant has remarkably broad effects.

GWAS showed the A391T polymorphism is associated with reduced arterial blood pressure, increased body mass index, and hyperlipidemia. Independent studies have also linked the variant to schizophrenia risk.

It has also been linked to adolescent idiopathic scoliosis, with the minor allele associated with greater spinal curvature, decreased height, increased BMI, and lower plasma manganese .

Practical Implications

If you carry one or two copies of the T allele, your intestinal cells absorb less manganese and zinc from food. This can weaken the gut barrier over time, potentially increasing susceptibility to intestinal inflammation and altering which bacteria thrive in your colon. The microbiome shifts resemble those seen in Crohn's disease and obesity, even in otherwise healthy people.

The reduced manganese transport affects enzymes throughout the body that require manganese as a cofactor, particularly those involved in building protective glycoproteins. This may explain the association with scoliosis (bone and cartilage development), lower blood pressure (vascular function), and neuropsychiatric effects (brain requires manganese for neurotransmitter metabolism).

Dietary intake of manganese becomes more important when you have this variant.

Higher dietary manganese intake was associated with lower BMI, higher HDL cholesterol, lower triglycerides, and reduced body fat percentage — effects that oppose the risks conferred by the genetic variant .

Interactions

The effects of this variant are most pronounced when combined with low dietary manganese intake or with other genetic variants affecting gut barrier function, metal metabolism, or inflammatory pathways. The microbiome alterations may interact with dietary factors that influence bacterial composition, such as fiber intake and fermented foods. No specific multi-SNP compound effects have been formally documented yet, but the microbiome-mediated effects suggest that variants in other IBD risk genes may compound the impact.

Your genome is under constant assault. Every day, ultraviolet radiation, tobacco smoke, air pollution, and industrial chemicals bombard your DNA with bulky chemical modifications called adducts¹¹ adducts
large chemical groups that bind to DNA bases, physically distorting the double helix and blocking replication and transcription. Left unrepaired, these lesions cause mutations that accumulate over a lifetime — the molecular basis of genomic aging and carcinogenesis.

ERCC2 (also known as XPD) is the helicase engine at the core of nucleotide excision repair (NER)²² nucleotide excision repair (NER)
the primary DNA repair pathway for removing bulky adducts, operating in two modes: global genome NER for random lesions throughout the genome, and transcription-coupled NER for damage blocking active genes. The rs13181 variant changes a single amino acid at position 751 — lysine (Lys) to glutamine (Gln) — in a region of the protein that mediates interaction with the CAK kinase subcomplex³³ CAK kinase subcomplex
a three-protein module (CDK7, cyclin H, MAT1) within the TFIIH transcription and repair complex; ERCC2 bridges CAK to the core TFIIH structure. The result is reduced helicase activity and measurably impaired DNA repair.

The Mechanism

ERCC2/XPD functions as a 5'-to-3' DNA helicase within the ten-subunit TFIIH complex. During NER, TFIIH unwinds roughly 30 base pairs of DNA around a lesion so that excision enzymes can cut out the damaged segment. The Gln751 substitution falls in the C-terminal domain where XPD contacts the CAK subcomplex and other TFIIH components; disrupting this interface reduces the helicase's opening efficiency.

Functional assays confirm the biochemical prediction. Sha Xiao et al. (2016)⁴⁴ Sha Xiao et al. (2016)
The ERCC2/XPD Lys751Gln polymorphism affects DNA repair of benzo[a]pyrene induced damage, tested in an in vitro model. Toxicol In Vitro transfected ERCC2-deficient CHO cells with either the Lys751 or Gln751 cDNA and challenged them with benzo[a]pyrene (the predominant carcinogen in tobacco smoke). Cells expressing Gln751 showed significantly greater DNA strand breaks, slower repair kinetics, and higher cellular toxicity — directly demonstrating that the variant reduces NER capacity for a real-world environmental carcinogen.

A parallel study by Zhang et al. (2017)⁵⁵ Zhang et al. (2017)
ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway. Chem Biol Interact found the same pattern for cisplatin-induced DNA crosslinks: Gln751 cells repaired platinum adducts less efficiently, accumulated more S-phase arrest, and showed altered p53 signaling compared to Lys751 cells.

The Evidence

The clinical consequence of impaired NER accumulates over a lifetime. Multiple large meta-analyses have examined rs13181 across cancer types:

Lung cancer: Zhan P et al. (2010)⁶⁶ Zhan P et al. (2010)
ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies. J Thorac Oncol pooled 22 case-control studies and found that Gln/Gln homozygotes (GG on the plus strand) have a 26% higher lung cancer risk versus Lys/Lys (OR 1.26, 95% CI 1.12–1.42). The elevated risk was consistent across Caucasian and, in most models, Asian subgroups.

Bladder cancer: Meta-analyses have also found modestly elevated bladder cancer risk in Gln carriers, with both heterozygotes and homozygotes showing elevated risk — consistent with a codominant effect. Notably, the bladder cancer association is stronger in smokers, a direct mechanistic consequence of tobacco carcinogens overwhelming impaired NER.

Head, neck, and other cancers: Associations have been reported for squamous cell carcinoma of the head and neck, glioma, esophageal cancer, and nasopharyngeal carcinoma, though the effect sizes are modest (OR 1.1–1.4) and consistency varies by population.

Longevity: Intriguingly, a Polish centenarian study (Polosak et al., Biogerontology 2010)⁷⁷ (Polosak et al., Biogerontology 2010) found that among 149 centenarians (mean age 101), both homozygous genotypes (Lys/Lys and Gln/Gln in coding notation, corresponding to TT and GG on the plus strand) were less frequent than in young controls. The heterozygous Lys/Gln (TG) genotype appeared enriched in extreme survivors. The same study found that XPD mRNA expression decreases significantly with age — lower NER gene expression in elderly tissues may represent an adaptive response, not pure deterioration. The longevity finding requires replication in larger cohorts but adds biological nuance to the simple "more repair = better" narrative.

Gene-environment interaction: The variant matters most in the context of carcinogen exposure. Affatato et al. (2004)⁸⁸ Affatato et al. (2004)
Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers found elevated chromosome aberration rates in smokers carrying variant alleles of a related ERCC2 variant (rs1799793, Asp312Asn) — not rs13181 (Lys751Gln) directly. The gene-environment interaction principle nonetheless supports that reduced NER capacity amplifies carcinogen-induced DNA damage, and reducing carcinogen exposure is especially impactful for Gln carriers.

Practical Actions

The Gln allele reduces your cellular repair throughput for bulky DNA adducts — this does not cause cancer, but it means that adducts accumulate faster and persist longer when encountered. The implications are dose-dependent: more carcinogen exposure translates into greater relative disadvantage compared to Lys/Lys individuals.

For Gln carriers, the highest-leverage interventions target carcinogen exposure (avoidance) and cellular antioxidant defenses (supplementation). Monitoring should focus on cancer-related screenings appropriate for the tissues most exposed to relevant carcinogens.

Interactions

ERCC2 carries a second well-studied variant, Asp312Asn (rs1799793), also in a conserved functional domain. Both variants have been associated with lung cancer and bladder cancer in overlapping meta-analyses. Some studies suggest that carrying risk alleles at both positions amplifies cancer susceptibility beyond either alone, particularly for lung and head-and-neck cancer in the context of tobacco exposure. This interaction is documented primarily in observational studies and warrants compound analysis when both genotypes are available.

Other relevant NER pathway genes include ERCC1 (the endonuclease partner of XPD in the NER complex) and XRCC1 (base excision repair). Multi-variant risk scores combining rs13181 with variants in these genes are under active investigation but are not yet at the level of actionable clinical guidance.

NOTCH3 encodes a cell-surface signalling receptor expressed almost exclusively in vascular smooth muscle cells. When NOTCH3 functions normally, it helps small arteries maintain their structure and tone throughout life. The Arg332Cys variant disrupts a cysteine in the sixth [epidermal growth factor-like (EGF-like) repeat | NOTCH3's extracellular domain is made of 34 EGF-like repeats, each stabilised by three disulfide bonds formed by six precisely-spaced cysteine residues. Odd-numbered cysteines in each repeat pair with even-numbered ones; adding or removing a cysteine breaks that pairing and causes the domain to misfold] of NOTCH3's extracellular domain — a change that, over decades, silently destroys the small arteries that supply deep brain structures. The resulting disease, [CADASIL | Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy — the name describes the anatomy: arteries (arteriopathy) supplying deep gray/white matter (subcortical) produce both small strokes (infarcts) and white matter damage (leukoencephalopathy)], is the most common inherited cause of stroke and vascular dementia in adults.

The Mechanism

NOTCH3's 34 EGF-like repeats depend on correctly paired disulfide bonds for structural integrity. Each repeat contains six cysteines that form three obligate pairs (C1-C2, C3-C4, C5-C6). The Arg332Cys substitution introduces an unpaired cysteine in repeat 6, breaking the rigid pairing rule. The [misfolded extracellular domain | The monomeric NOTCH3 ECD cannot be cleared by normal proteostasis and accumulates at the vessel wall surface. This aggregate forms the pathological hallmark of CADASIL: GOM (granular osmiophilic material) deposits visible on electron microscopy of skin or brain vessel biopsies] cannot fold correctly, and the protein accumulates on the surface of smooth muscle cells rather than participating in normal signalling.

Over years of accumulation, the [smooth muscle cells | The principal cellular target in CADASIL — smooth muscle cells in small penetrating arteries degenerate and are replaced by fibrosis, thickening the vessel wall and reducing the lumen. The result is chronic hypoperfusion and vulnerability to small infarcts in territory the arteries supply: deep white matter, basal ganglia, thalamus, brainstem] progressively degenerate and are replaced by fibrosis. The small penetrating arteries supplying deep brain structures — the lenticulostriate arteries, thalamic perforators, brainstem perforators — narrow and stiffen, eventually causing lacunar infarcts and the characteristic white matter hyperintensities visible on FLAIR MRI. Because NOTCH3 is expressed almost exclusively in smooth muscle cells (not endothelium or neurons), the pathology is pure vasculopathy: neurons die not from a primary genetic defect but from the vascular failure upstream.

The Arg332Cys variant is located in exon 6 — a [less common mutation site for CADASIL | The majority of CADASIL mutations cluster in exons 3-4 (EGF-like repeats 1-5). Exon 6 mutations are rarer and may carry slightly different phenotypic features, including a lower rate of anterior temporal lobe involvement and possible lower penetrance in some families], contrasting with the more common exon 3-4 hotspot. Regardless of the exact exon location, any cysteine-altering NOTCH3 mutation is classified as pathogenic by the diagnostic criterion [defined by Rutten et al. | 2014, Expert Rev Mol Diagn, PMID 24844136]: gain or loss of a cysteine residue in any of the 34 EGF-like repeats.

The Evidence

A landmark UK Biobank analysis of 200,632 participants by Cho et al.¹¹ landmark UK Biobank analysis of 200,632 participants by Cho et al.
J Neurol Neurosurg Psychiatry 2021 found cysteine-altering NOTCH3 variants in approximately 1 in 450 individuals in the general population — far more than the 1 in 15,000 estimated from classic CADASIL clinical case series, suggesting profound underdiagnosis. Carriers had a 2.33-fold increased stroke risk (p=0.0004), a 5-fold increased vascular dementia risk (p=0.007), significantly greater white matter hyperintensity volume, elevated lacune burden (5.97-fold increase), and increased cerebral microbleeds (4.38-fold increase) — the full neuroimaging signature of CADASIL, present in individuals who had never received a clinical diagnosis.

Phenotypic data specific to Arg332Cys comes from case series. Li et al. 2020²² Li et al. 2020
Annals of Translational Medicine characterized 12 published Arg332Cys cases with a mean symptom onset age of 37.8 ± 9.4 years, earlier than the 47-year average across all CADASIL mutations per GeneReviews. Stroke or TIA was the presenting event in 83.3%, cognitive decline in 58.3%, and psychiatric disturbance in 50%. Sano et al. 2011³³ Sano et al. 2011
Internal Medicine documented phenotypic heterogeneity even within families carrying identical Arg332Cys mutations: one proband presented with syncope only, another with recurrent ischemic events followed by intracranial hemorrhage — illustrating that clinical course is not precisely predictable from the genotype alone.

No proven disease-modifying therapy exists for CADASIL. Thrombolytic therapy and oral anticoagulants [probably increase intracerebral hemorrhage risk | GeneReviews CADASIL: cerebral microbleeds, present in 31-69% of CADASIL patients, represent fragile small vessels at high bleeding risk; anticoagulants that would normally benefit embolic stroke are counterproductive here] and are generally avoided. Antiplatelet therapy may reduce ischemic event risk and is widely used in practice, though randomized trial evidence is lacking. Blood pressure control is a clear priority: faster disease progression is documented in individuals with elevated systolic blood pressure.

Practical Actions

The central management goals for Arg332Cys carriers are: (1) secure a neurology referral and establish baseline MRI before symptoms appear, (2) control all modifiable vascular risk factors aggressively — especially blood pressure and smoking — because these accelerate an already progressive disease, (3) avoid iatrogenic hemorrhage from thrombolytics or anticoagulants in the acute stroke setting, and (4) enable cascade family testing so other carriers are identified before their first infarct.

Migraine with aura, present in 30-75% of CADASIL patients across mutations, is often the earliest symptom. Triptans have been used safely in CADASIL patients in published series without documented vascular complications, though the evidence base is observational. Standard migraine prophylaxis (beta-blockers, topiramate, valproate) follows general guidelines.

Pregnancy carries a modestly elevated risk of neurological events, particularly in the peripartum period. Maternal-fetal medicine consultation is recommended before conception. Antiplatelet therapy in pregnancy should be individualized with specialist input.

Interactions

No single-variant gene-gene compound action is specifically documented for rs137852641, but the broader CADASIL phenotype interacts strongly with modifiable vascular risk factors. Carriers who also have hypertension-amplifying variants (AGT, ACE), dyslipidaemia variants (APOE4, LDLR), or pro-inflammatory variants (IL-6, CRP) may have accelerated white matter lesion progression — though the interaction evidence is observational rather than established from controlled genetic studies.

Every steroid hormone your body makes — cortisol, aldosterone, testosterone, estrogen — begins with a single critical step: getting cholesterol from the cytoplasm into the inner mitochondrial membrane where the first enzyme of the steroid synthesis pathway lives. Steroidogenic Acute Regulatory protein (STAR)¹¹ Steroidogenic Acute Regulatory protein (STAR)
Encoded by the STAR gene on chromosome 8; a 30 kDa protein rapidly induced by ACTH and LH to enable acute steroidogenesis is the gatekeeper of this transfer — without it, the entire steroidogenic cascade stalls regardless of how much cholesterol the cell has in reserve. The p.Ala218Val variant (c.653C>T, rs137852690) substitutes a valine for an alanine at position 218 of the STAR protein, located within the START cholesterol-binding domain, and eliminates steroidogenic activity entirely.

The Mechanism

The START domain of STAR forms a hydrophobic tunnel that binds a single cholesterol molecule and facilitates its transfer across the outer mitochondrial membrane. Alanine 218 sits within this cholesterol-binding pocket²² Alanine 218 sits within this cholesterol-binding pocket
The START (StAR-related lipid transfer) domain spans residues 63–285 of the mature STAR protein and is the evolutionarily conserved lipid-binding module, where it contributes to the precise geometry required for substrate binding. The substitution of valine (which has a bulkier branched side chain than alanine) disrupts critical residue interactions at the cholesterol- binding site, increasing local alpha-helix rigidity while reducing the protein's overall flexibility — changes that compromise cholesterol binding and release.

Transfection studies in COS-1 cells³³ Transfection studies in COS-1 cells
A standard cell-based assay for steroidogenic activity using cells expressing P450scc/adrenodoxin alongside STAR constructs show that A218V produces zero steroidogenesis-enhancing activity — indistinguishable from an empty vector control. The protein is made but cannot perform its function. Arakane et al. further showed that A218V StAR is inactive not only in intact cells but also when added to isolated mitochondria⁴⁴ Arakane et al. further showed that A218V StAR is inactive not only in intact cells but also when added to isolated mitochondria
Demonstrating that the defect is intrinsic to the protein, not a folding or targeting problem upstream, while simultaneously establishing that STAR acts on the outside of the outer mitochondrial membrane rather than needing to enter the organelle. Structural analysis confirms the mechanism: the A218V substitution produces incorrect protein folding⁵⁵ Structural analysis confirms the mechanism: the A218V substitution produces incorrect protein folding
Bose et al. 1998: spectroscopic analysis of purified mutant StARs revealed that inactive mutants tend to form incorrect intermolecular beta-sheets rather than the predominantly alpha-helical structure of wild-type.

The Evidence

A218V is classified as pathogenic by ClinVar⁶⁶ pathogenic by ClinVar
VCV000008993; 5 concordant submissions, 2-star review status (criteria provided, multiple submitters, no conflicts) for congenital lipoid adrenal hyperplasia (lipoid CAH; OMIM 201710). The condition disrupts the synthesis of all adrenal and gonadal steroid hormones simultaneously — cortisol, aldosterone, androgens, and estrogens are all produced through the same cholesterol-import step.

The clinical consequences depend on the specific genotype. Homozygous A218V carriers, or compound heterozygotes pairing A218V with a second loss-of-function STAR allele, develop classic lipoid CAH: severe adrenal crisis in the neonatal period or early infancy, with life-threatening salt-wasting (from absent aldosterone), hypoglycemia and cortisol deficiency, and complete sex reversal in 46,XY individuals (phenotypic females because no testicular testosterone was made during fetal development). Kim's 2014 review of the literature⁷⁷ Kim's 2014 review of the literature
PMID 25654062 describes most cases presenting with "signs of severe adrenal failure in early infancy." Notably, 46,XX females with classic lipoid CAH can have spontaneous puberty because the ovary, unlike the adrenal gland, is relatively protected from cholesterol accumulation during fetal and early childhood life, preserving some function until puberty.

A218V was first characterized in a 1997 Japanese cohort study⁸⁸ in a 1997 Japanese cohort study
Nakae et al., Human Molecular Genetics, PMID 9097960 alongside six other STAR mutations; all variants affecting the C-terminus showed no residual activity, explaining the severity of classic lipoid CAH. A more recent Iranian cohort study by Aghaei et al. 2023⁹⁹ Aghaei et al. 2023
PMID 37004560 reported A218V in twelve 46,XY patients presenting with male pseudohermaphroditism, providing the first structural explanation for its pathogenicity through molecular dynamics simulation.

Practical Implications

Heterozygous carriers of A218V have no symptoms — one functional STAR allele is sufficient for normal steroidogenesis. The relevance is entirely reproductive: carrier couples face a 25% chance per pregnancy of a homozygous or compound heterozygous child requiring lifelong hormone replacement from birth. Newborn screening programs in most countries do not routinely test for STAR variants; affected neonates present with salt-wasting adrenal crisis and can die before diagnosis if the underlying genetic cause is not recognized.

Individuals confirmed homozygous for A218V (or compound heterozygotes with a second null allele) require immediate endocrinology consultation. Management is lifelong: hydrocortisone and fludrocortisone replace adrenal hormones; sex steroid replacement is initiated at the expected age of puberty and tailored to the individual's gender identity; fertility is generally absent in 46,XY individuals but may be partially preserved in 46,XX individuals with mild forms of the disease.

Interactions

A218V is documented as a compound heterozygous pair with rs137852689 (STAR p.Arg217Thr)¹⁰¹⁰ rs137852689 (STAR p.Arg217Thr)
An adjacent missense variant also causing loss of StAR activity, reported in the same patient by Katsumata et al. 1999, where neither allele alone causes disease but both together eliminate steroidogenic function. This adjacent-residue compound heterozygosity illustrates that the region around position 217–218 of the START domain is critical to cholesterol-binding geometry. Clinically, A218V can also pair with any other STAR loss-of-function variant (splice site mutations, frameshift, nonsense alleles such as Q258X) to produce the same classic phenotype.

The mitochondrial trifunctional protein (MTP)¹¹ mitochondrial trifunctional protein (MTP)
MTP is a hetero-octameric enzyme complex in the inner mitochondrial membrane consisting of four HADHA-encoded alpha subunits and four HADHB-encoded beta subunits. Together they catalyze the last three steps of long-chain fatty acid beta-oxidation. is the enzymatic workhorse for burning long-chain dietary fats. The HADHA alpha subunit alone carries three distinct catalytic activities: long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD), and long-chain 3-ketoacyl-CoA thiolase. The p.Glu510Gln substitution (c.1528G>C, NM_000182.5) specifically abolishes the LCHAD activity while leaving the other two activities partially intact — a distinction that defines isolated LCHAD deficiency as a phenotypically distinct disorder from complete MTP deficiency.

This glutamic-to-glutamine change at position 510 is by far the most prevalent pathogenic HADHA variant in European populations, accounting for the large majority of LCHAD deficiency cases worldwide. In the Kashubian ethnic group of northern Poland, carrier frequency reaches 1 in 57 individuals²² 1 in 57 individuals
Nedoszytko et al., PLoS One, 2017 — the Kashubian founder effect suggests a single ancestral mutation event; general Polish carrier rate is approximately 1 in 187, reflecting a documented founder effect. Globally the heterozygous carrier frequency is approximately 1 in 275 people, making LCHAD deficiency one of the more common fatty acid oxidation disorders after MCAD deficiency.

The Mechanism

Glutamate 510 sits within the catalytic core of the LCHAD domain, where its negatively charged carboxylate side chain participates in the proton transfer mechanism of 3-hydroxyacyl-CoA dehydrogenation. Replacing glutamate with glutamine removes the charge while preserving volume — a conservative substitution at the sequence level but catastrophic for catalysis. The result is near-complete loss of LCHAD activity; homozygous cells cannot oxidize long-chain 3-hydroxyacyl-CoA intermediates (C12–C18 chain length).

When LCHAD fails, long-chain fatty acids cannot complete beta-oxidation. Toxic long-chain 3-hydroxyacylcarnitine species (particularly C16:OH and C18:OH acylcarnitines) accumulate in plasma and tissues. These are not merely inert intermediates — they are detergent-like molecules that disrupt mitochondrial membrane integrity, cardiac conduction, retinal pigment epithelial cells, and peripheral nerve myelin sheaths. Cells that rely heavily on long-chain fat for energy (cardiac muscle, skeletal muscle, retina, liver) are disproportionately affected.

The Evidence

Clinical spectrum in homozygotes: A multi-center study of LCHAD and MTP-deficient patients³³ LCHAD and MTP-deficient patients
Olpin et al., J Inherit Metab Dis, 2005 — comprehensive biochemical and clinical profiling across the phenotypic spectrum established that isolated LCHAD deficiency from the Glu510Gln mutation produces a moderately severe phenotype spanning neonatal presentation (cardiomyopathy, hypoketotic hypoglycemia) to a later-onset neuromyopathic form.

Outcomes under modern management: In a cohort of 67 individuals diagnosed through newborn screening⁴⁴ 67 individuals diagnosed through newborn screening
Mütze et al., Ann Clin Transl Neurol, 2024 — 54 screened, 13 symptomatic; LCHAD and MTP deficiency combined, all screened LCHAD patients survived. However, even with early intervention, 94% had a symptomatic disease course, 82% developed myopathy, 17% retinopathy, and 22% peripheral neuropathy — underscoring that dietary treatment prevents death but does not fully prevent long-term morbidity. Dietary adherence declined from 75% in infancy to only 12% by age 10, a major clinical challenge.

Retinopathy and visual outcomes: Among 40 patients stratified by diagnosis pathway⁵⁵ 40 patients stratified by diagnosis pathway
Gillingham et al., J Inherit Metab Dis, 2024 — 12 symptomatic, 28 via NBS or family history, early diagnosis through newborn screening produced significantly better visual acuity, ERG amplitudes, contrast sensitivity, and visual fields than symptomatic diagnosis. Despite this advantage, chorioretinopathy progressed with age in both groups. An Austrian cohort of 14 Glu510Gln homozygotes showed retinopathy in 57%, cardiomyopathy in 50%, and hepatopathy in 36%⁶⁶ retinopathy in 57%, cardiomyopathy in 50%, and hepatopathy in 36%
Karall et al., Orphanet J Rare Dis, 2015 — all patients homozygous for c.1528G>C, majority identified by NBS, with a median of 9 hospitalizations per patient.

The unique maternal-fetal link: LCHAD deficiency is distinctive among metabolic disorders for its effect on the carrier mother during pregnancy. When a carrier mother gestates an affected (homozygous) fetus, the fetus floods the maternal circulation with long-chain 3-hydroxyacylcarnitines it cannot process. In a heterozygous mother whose own LCHAD capacity is already reduced by 50%, this metabolic load overwhelms hepatic processing⁷⁷ this metabolic load overwhelms hepatic processing
Bellig, Adv Neonatal Care, 2004; Ibdah et al., Mol Genet Metab, 2000 and causes HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) or acute fatty liver of pregnancy (AFLP) in the third trimester — conditions with significant maternal and fetal mortality. This makes LCHAD deficiency one of the few recessive disorders where the heterozygous state has a clinically documented, albeit pregnancy-specific, phenotype.

Practical Actions

For homozygous individuals, management is lifelong and centers on eliminating the long-chain fat substrate: a diet restricted to no more than 15–30% of energy from long-chain fat, with medium-chain triglycerides supplying the remainder of fat-based energy. MCT oil and triheptanoin (C7 triglyceride, Dojolvi) are metabolized via MCAD and MCKAT without requiring HADHA activity. Fasting must be avoided — when glucose stores are depleted, the body cannot substitute long-chain fat oxidation. Every hospitalization, surgical procedure, or febrile illness requires IV dextrose supplementation. Long-chain 3-hydroxyacylcarnitine monitoring (C16:OH, C18:OH acylcarnitines) guides dietary adequacy.

Annual ophthalmology evaluation with retinal imaging (OCT, ERG) is essential given the high retinopathy rate, even in well-managed patients. Periodic nerve conduction studies detect subclinical peripheral neuropathy before it becomes symptomatic.

Carrier mothers planning pregnancy should inform their obstetrician and undergo carrier testing of their partner. If both partners are carriers, LCHAD-deficient fetuses can be detected prenatally; affected neonates must be identified within days of birth to begin dietary treatment before metabolic crisis.

Interactions

The Glu510Gln variant can occur in compound heterozygosity with other HADHA pathogenic variants, producing variable phenotypic severity depending on the second allele's residual activity. Variants causing complete MTP deficiency (abolishing all three alpha-subunit activities) produce a more severe phenotype than Glu510Gln homozygosity.

Pathway partners include HADHB (encoding the MTP beta subunit harboring thiolase activity); biallelic HADHB mutations cause the isolated MTP neuropathic/myopathic phenotype without LCHAD deficiency's characteristic retinopathy. Other fatty acid oxidation enzymes — ACADVL (rs113994167), ACADM — act upstream in the same pathway; concurrent variants there amplify the metabolic burden.

The FTO (fat mass and obesity-associated) gene spans chromosome 16 and contains multiple independently associated genetic variants across different introns. While the best-known FTO variants (rs9939609, rs1421085) cluster in intron 1 and drive the well-replicated obesity association, rs1420318 occupies a different region of the gene — intron 8¹¹ intron 8
The eighth non-coding interval within the FTO pre-mRNA, approximately 100 kb downstream of the intron-1 obesity cluster. The two regions are in low linkage disequilibrium²² low linkage disequilibrium
r² ≈ 0.11 in CEU populations, indicating that knowing your rs1420318 genotype tells you very little about your rs9939609 genotype — making rs1420318 an essentially independent locus within the same gene.

rs1420318 is in very high LD with rs1108086 (r² = 0.95 in Europeans), suggesting these two intron-8 variants tag the same underlying haplotype and likely have correlated effects.

The Evidence

Published evidence for rs1420318 comes from two independent lines of research. The first is a 2011 study by Guo et al.³³ Guo et al.
The fat mass and obesity associated gene, FTO, is also associated with osteoporosis phenotypes. PLoS One, 2011 that tested 141 FTO SNPs for associations with bone mineral density (BMD) in two Chinese Han cohorts (N=818 and N=809) and one Caucasian cohort (N=2,286). In Chinese populations, six intron-8 FTO SNPs — all in high mutual LD — showed significant associations with hip BMD (combined p = 1.47×10⁻⁴ to 4.99×10⁻⁴), with each minor allele copy associated with increased hip BMD (β ≈ 0.015–0.025). In the Caucasian sample, rs1420318 specifically showed a nominal association with spine BMD (p = 6.14×10⁻³), though this did not survive multiple-testing correction. The connection between FTO and bone health is biologically plausible: FTO is an RNA demethylase⁴⁴ RNA demethylase
Removes N6-methyladenosine (m6A) modifications from mRNA, influencing translation efficiency of downstream target genes with expression in osteoblast-rich tissues, and body weight itself (which the intron-1 variants influence) is a major determinant of bone loading.

The second line of evidence comes from a 2013 genetic study by Wang et al.⁵⁵ Wang et al.
Genetic variants in the fat mass- and obesity-associated (FTO) gene are associated with alcohol dependence. Journal of Molecular Neuroscience, 2013 that scanned 167 FTO SNPs for associations with alcohol use disorder in two Caucasian populations (COGA: 660 cases/400 controls; SAGE: 623 cases/1,016 controls). rs1420318 ranked among the top three FTO variants associated with alcohol dependence in the SAGE sample (p = 0.00086). No specific odds ratio by genotype was reported. This finding echoes observations that the FTO gene region influences reward and appetite signaling more broadly than just adiposity.

Both associations remain emerging⁶⁶ emerging
Not yet replicated with genome-wide significance or in multiple independent cohorts at the same locus evidence — neither reached genome-wide significance (p < 5×10⁻⁸), and the BMD finding did not replicate across the Chinese and Caucasian samples in the same study.

Practical Implications

Because rs1420318 is not in LD with the rs9939609/rs1421085 intron-1 obesity cluster, it does not capture the established IRX3/IRX5 thermogenesis mechanism. The variant's location in intron 8 puts it in a distinct regulatory context within the FTO gene. For carriers of the A allele — which is particularly common in African populations (~53%) and South Asian populations (~34%), but rare in Europeans (~12%) — the available data suggest two areas worth attention: bone mineral density monitoring (particularly spine BMD, where the nominal Caucasian signal was observed), and mindful engagement with alcohol, given the association signal in the SAGE cohort.

These recommendations reflect current evidence and should be revisited as larger-scale studies provide clearer replication.

Interactions

rs1420318 and rs1108086 (r² = 0.95) are on the same intron-8 haplotype and likely tag the same functional signal. If you carry the A allele at rs1420318, you almost certainly carry the corresponding allele at rs1108086, and vice versa — any compound action combining these two variants would largely be redundant.

The intron-8 haplotype is independent of the intron-1 obesity cluster (rs9939609, rs1421085, rs8050136). Individuals who carry both the intron-1 risk allele and the intron-8 A allele are carrying two independently inherited FTO variants with potentially different biological effects.

For decades, endometriosis research focused almost exclusively on hormonal mechanisms — oestrogen-driven tissue proliferation, progesterone resistance, and the surgical removal of lesions. A 2021 landmark study changed that picture by pinpointing a gene in the neuropeptide signalling system as the first genetically validated nonhormonal drug target¹¹ first genetically validated nonhormonal drug target
A drug target is "genetically validated" when genetic variation in the gene — not just pharmacological inhibition — is associated with the disease, reducing the risk that early drug failure reflects an irrelevant target for endometriosis. That gene is NPSR1 — neuropeptide S receptor 1 — and the variant at rs142885915 sits within it.

The Mechanism

NPSR1²² NPSR1
neuropeptide S receptor 1; a G-protein-coupled receptor activated by the 14-amino-acid peptide neuropeptide S (NPS), primarily expressed in inflammatory cells including macrophages, mast cells, and T-cells as well as in the nervous system mediates pro-inflammatory signalling through two parallel G-protein pathways (Gαq/PLC and Gαs/cAMP). Activation triggers calcium mobilisation, ERK cascade signalling, and — critically in the endometriosis context — expression of pro-inflammatory cytokines including TNF-α, IL-6, PTGS2, and CXCL8 in peritoneal cells.

The rs142885915 variant is an intronic insertion/deletion located within the NPSR1 gene on chromosome 7p14.3. The deletion allele (D) tags a regulatory haplotype associated with altered NPSR1 expression or splicing in inflammatory tissues. The NPSR1 gene itself is expressed at low-to-moderate levels across most adult tissues but shows notable expression in the kidney, lung, and gastrointestinal tract — all sites with documented NPSR1-mediated inflammatory phenotypes. In the peritoneal cavity, where endometriosis lesions form, NPSR1 signalling amplifies the neuroinflammatory environment that drives pain, lesion growth, and immune evasion.

The Evidence

Tapmeier et al. 2021³³ Tapmeier et al. 2021
Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis. Sci Transl Med 13:eabd6469 combined family-based sequencing, targeted association analysis, and preclinical pharmacology to establish NPSR1 as a disease-relevant target. Starting from 32 multi-affected families with severe endometriosis, the investigators found significant overrepresentation of predicted deleterious low-frequency coding variants in NPSR1 (P=7.8×10⁻⁴). In a targeted association cohort of 3,194 surgically confirmed cases and 7,060 controls, the intronic deletion rs142885915 showed robust association specifically with stage III/IV (deep infiltrating) endometriosis: OR 1.23 (95% CI 1.09–1.39, P=5.2×10⁻⁵). Critically, the association was replicated in rhesus macaque pedigrees (849 members), linking the locus to spontaneous peritoneal disease in a non-human primate model. The therapeutic proof-of-concept was strong: the NPSR1 inhibitor SHA 68R blocked NPSR1-mediated signalling and proinflammatory TNF-α release in vitro (P<0.01), and led to a significant reduction of both inflammatory cell infiltrate and abdominal pain in mouse endometriosis models (P<0.05).

The locus was subsequently featured in the largest endometriosis GWAS to date: Rahmioglu et al. 2023⁴⁴ Rahmioglu et al. 2023
The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat Genet 55:423–436, which analysed 762,600 participants and identified multiple susceptibility regions with enriched genetic architecture shared between endometriosis, other pain conditions, and inflammatory diseases — a genetic signal that validates the neuroinflammatory framing of the NPSR1 association.

Drug development has accelerated: a 2025 medicinal chemistry study ⁵⁵ Design of peripherally biased NPSR1 antagonists. Bioorg Med Chem Lett, 2025 developed next-generation peripherally restricted NPSR1 antagonists that blocked NPS-triggered cytokine expression (IL-6, PTGS2, CXCL8) in human fibroblasts with sub-nanomolar potency, signalling active therapeutic development at this target.

Practical Actions

The NPSR1 pathway operates through neuroinflammation rather than oestrogen-driven proliferation. This distinction has practical implications for symptom management. Carriers of the deletion allele may find that hormonal treatments (combined oral contraceptives, progestins) manage some aspects of endometriosis but leave a neuroinflammatory pain component partially or fully unaddressed. Awareness of this gap can guide more targeted discussions with specialists.

Pain management approaches that target neuroinflammatory pathways — including COX-2 inhibitors (such as high-dose NSAIDs), mast cell stabilisers, and emerging NPSR1 antagonists (currently in preclinical and early drug development stages) — are mechanistically aligned with the NPSR1-driven component of endometriosis pain. Omega-3 fatty acids (EPA/DHA) reduce peritoneal prostaglandin production via competitive inhibition of the COX/PTGS2 pathway that NPSR1 activates, providing a supplementation-level intervention that addresses the relevant biology.

Because rs142885915 is specifically associated with stage III/IV endometriosis, carriers with symptoms consistent with deep infiltrating disease should discuss thorough laparoscopic staging with a specialist — the variant flags a mechanistic bias toward the advanced, inflammatory phenotype that most benefits from precise surgical characterisation.

Interactions

NPSR1 is also associated with asthma, inflammatory bowel disease, panic disorder, and post-traumatic stress disorder in the broader literature — all conditions sharing a neuroinflammatory or neuroimmune component. Carriers with endometriosis who also carry variants in inflammatory pathway genes (e.g. TNF, IL-6, COX-2 pathway variants) may experience additive neuroinflammatory burden, though no compound-genotype endometriosis risk data currently exists for NPSR1 in combination with other loci.

Adiponectin is sometimes called the body's metabolic guardian¹¹ metabolic guardian
Secreted exclusively by adipose tissue; higher levels paradoxically correlate with leanness rather than obesity — a hormone that simultaneously sensitizes cells to insulin, suppresses vascular inflammation, and protects the endothelium from atherosclerotic damage. The rs1501299 variant, also known as +276G>T, sits in intron 2 of the ADIPOQ gene and influences how much adiponectin your body produces. Carriers of the T allele tend to circulate lower levels of this protective adipokine, a difference that emerges most clearly under metabolic stress and shapes how well your body responds to dietary interventions.

The Mechanism

Because the +276G>T variant falls within an intron — not a protein-coding region — it does not change the amino acid sequence of adiponectin. Instead, it likely acts as a regulatory element affecting transcriptional efficiency²² regulatory element affecting transcriptional efficiency
Intronic sequences can contain enhancer elements that influence mRNA production; linkage disequilibrium with 3′UTR variants may also contribute. Some evidence suggests rs1501299 is in linkage disequilibrium with functional variants near the 3′ untranslated region that more directly regulate adiponectin mRNA stability or expression level. The practical result is measurable: in studies of obese adults, total adiponectin levels differed significantly by genotype³³ total adiponectin levels differed significantly by genotype
GG: 20.2 ± 2.4 ng/dl; GT: 15.8 ± 3.4 ng/dl; TT: 13.7 ± 1.4 ng/dl — TT individuals carried about 32% lower adiponectin than GG homozygotes.

Lower adiponectin has downstream consequences. The protein normally activates AMP-activated protein kinase (AMPK)⁴⁴ AMP-activated protein kinase (AMPK)
AMPK is often called the cell's "energy sensor"; its activation improves glucose uptake and fat oxidation in muscle and liver, increasing insulin sensitivity. It also suppresses production of pro-inflammatory cytokines like TNF-α and IL-6, and prevents monocyte adhesion to the vascular endothelium — one of the earliest steps in atherosclerotic plaque formation. When adiponectin is chronically low, each of these pathways operates at reduced capacity.

The Evidence

The strongest and most clinically relevant finding for rs1501299 is its impact on metabolic response to dietary intervention⁵⁵ metabolic response to dietary intervention
Effect on basal metabolic parameters is modest; impact on treatment response is where this variant stands out. A series of studies from Spanish research groups examined obese Caucasian patients randomized to different hypocaloric diets. Consistently across these trials, GG homozygotes showed dramatically better improvements than T-allele carriers in adiponectin levels, fasting insulin, HOMA-IR (insulin resistance index), LDL cholesterol, and total cholesterol — even when both groups lost similar amounts of weight. In one 3-month Mediterranean diet study, GG carriers reduced fasting glucose by 4.8 mg/dL and insulin by 3.6 mUI/L; T-allele carriers showed virtually no improvement (0.5 mg/dL and a slight increase in insulin, respectively). A 9-month trial comparing high-protein vs standard diets⁶⁶ 9-month trial comparing high-protein vs standard diets
Both diets enriched with unsaturated fats; n=226 found similar divergence: only GG carriers showed significant adiponectin elevation regardless of diet type.

A separate line of evidence links rs1501299 to cardiovascular disease risk, but with important nuances⁷⁷ cardiovascular disease risk, but with important nuances
Direction of effect shifts in diabetic vs non-diabetic populations. A 2012 meta-analysis of 37 studies found the T allele modestly protective overall for CVD (OR 0.90, 95% CI 0.83–0.97), particularly for coronary heart disease (OR 0.89). But a focused meta-analysis of 15 studies in type 2 diabetic patients found TT homozygotes specifically had reduced CVD risk compared to G-allele carriers (OR 0.74, 95% CI 0.58–0.94). This paradox may reflect complex interactions between genotype, metabolic state, and circulating adiponectin in the diabetic context. A larger 2018 meta-analysis of 65 studies found no significant CVD association for rs1501299. The metabolic syndrome and diet-response evidence is more consistent than the cardiovascular disease association.

At the level of adiponectin physiology, rs1501299 also interacts with dietary fiber intake⁸⁸ interacts with dietary fiber intake
Effect is pronounced at low fiber — above the highest tertile of intake, genotype difference narrows. In 741 Greek children, GG homozygotes showed significantly higher adiponectin concentrations than T-allele carriers when dietary fiber was low, but the difference largely disappeared at high fiber intake — suggesting that adequate fiber can partially compensate for the T allele's lower transcriptional baseline.

Practical Implications

For GG homozygotes — the genotype associated with higher baseline adiponectin — standard metabolic monitoring applies, and they can expect robust adiponectin responses to dietary improvement. For T-allele carriers (GT and especially TT), the evidence points to two practical conclusions: first, metabolic interventions that work well for GG individuals may underperform, particularly standard caloric restriction or Mediterranean-style diets; second, increasing dietary fiber and favoring unsaturated fatty acids (both mono- and polyunsaturated) over saturated fats appears to narrow the genotype gap. TT carriers in particular should monitor HOMA-IR and fasting insulin as markers of insulin resistance trajectory, since their adiponectin-mediated protection is structurally lower.

The fiber interaction is actionable: across studies, adequate dietary fiber (above roughly the upper tertile of population intake, corresponding to approximately 25–30+ grams per day for adults) appears to attenuate the metabolic disadvantage associated with T-allele carriage. This is one of the cleaner gene-nutrient interaction findings in the ADIPOQ literature.

Interactions

rs1501299 is frequently studied alongside two other ADIPOQ variants — rs266729⁹⁹ rs266729
Promoter variant; G allele lowers adiponectin and increases CVD risk and rs2241766¹⁰¹⁰ rs2241766
+45T>G, exon variant; GG associated with higher adiponectin — all three together form the major haplotypic architecture of the ADIPOQ locus. Studies show rs266729 and rs2241766 have stronger and more consistent cardiovascular disease associations than rs1501299 alone. When these variants co-occur unfavorably, their combined effect on adiponectin suppression and CVD risk is additive. The third ADIPOQ variant in this encyclopedia, rs17300539 (-11391G>A), is a promoter variant that also modulates transcription; combined carriage of low-adiponectin alleles across these loci compounds the effect.

Sex modifies the rs1501299-metabolic syndrome relationship: meta-regression in one T2D meta-analysis identified significant effects of the GT genotype specifically in males, while other studies report stronger adiponectin associations in women. Fiber intake, as described above, is the most robustly documented environmental modifier.

Neuropeptide Y¹¹ Neuropeptide Y
NPY is a 36-amino-acid peptide and the most abundant neuropeptide in the human brain. It acts through five receptor subtypes (Y1-Y5) to regulate feeding, stress, anxiety, pain, and cardiovascular function (NPY) is the brain's most abundant neuropeptide and one of the most potent appetite-stimulating molecules known. But NPY does far more than drive hunger — it serves as a critical brake on the stress response, dampening anxiety, modulating pain perception, and influencing cardiovascular tone. The rs16147 variant sits in the promoter region of the NPY gene, directly affecting how much NPY your cells produce, particularly under stress. This makes it a rare example of a single variant with documented effects across stress resilience, body weight regulation, migraine susceptibility, and blood pressure.

The Mechanism

The rs16147 T>C substitution occurs 399 base pairs upstream of the NPY gene's transcription start site, in a region that regulates gene expression. The T allele creates a stronger binding site for transcription factors, leading to higher NPY expression, particularly under stress²² higher NPY expression, particularly under stress
Zhang K et al. Association of neuropeptide Y promoter polymorphism (rs16147) with perceived stress and cardiac vagal outflow in humans. Sci Rep, 2016. The C allele reduces transcription factor binding affinity³³ transcription factor binding affinity
The C-variant decreases protein binding compared to the T-allele in electrophoretic mobility shift assays, suggesting weaker promoter activation, resulting in lower NPY output when the system is challenged.

This is not a simple on-off switch. Postmortem brain analysis of 107 human anterior cingulate cortex samples⁴⁴ 107 human anterior cingulate cortex samples
Zhou Z et al. Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum Mutat, 2010 showed that the rs16147 genotype accounts for a meaningful portion of individual variation in NPY mRNA levels in this region — a brain area central to emotional regulation and decision-making. The variant's effects are context-dependent: differences between genotypes become most pronounced under conditions of chronic stress or early adversity.

The Evidence

Stress resilience and mental health. In a study of 1,123 healthy Han Chinese adults⁵⁵ 1,123 healthy Han Chinese adults
Zhang K et al. Association of neuropeptide Y promoter polymorphism (rs16147) with perceived stress and cardiac vagal outflow in humans. Sci Rep, 2016, TT homozygotes showed significantly enhanced cardiac vagal outflow⁶⁶ cardiac vagal outflow
Vagal tone reflects parasympathetic nervous system activity. Higher vagal tone is associated with better stress recovery, emotional regulation, and cardiovascular health under chronic high stress compared to CC homozygotes — indicating greater parasympathetic resilience. No genotype differences emerged in the low-stress group, confirming the gene-by-environment pattern. Research in US military veterans⁷⁷ US military veterans
Watkins LE et al. Association between functional polymorphism in neuropeptide Y gene promoter rs16147 and resilience to traumatic stress in US military veterans. J Clin Psychiatry, 2017 found the T allele protective against PTSD intrusion symptoms in combat-exposed populations. The rs16147 variant also interacts with early childhood adversity to predict anxiety and depressive symptoms in young adults, with the C allele functioning as a vulnerability factor.

Appetite and body weight. NPY is one of the most potent orexigenic⁸⁸ orexigenic
Appetite-stimulating. NPY acts through hypothalamic Y1 and Y5 receptors to increase food intake, with a preferential effect on carbohydrate consumption peptides in the brain. A meta-analysis of 9 studies⁹⁹ meta-analysis of 9 studies
Yeung EH et al. Comprehensive evaluation of the neuropeptide-Y gene variants in the risk of obesity. Obesity, 2015 found the T allele significantly associated with obesity risk (OR 1.27, 95% CI 1.04-1.55), including higher BMI, waist circumference, triglycerides, and body fat percentage. A longitudinal study following 306 individuals from infancy to age 19¹⁰¹⁰ longitudinal study following 306 individuals from infancy to age 19
Hohmann S et al. Increasing association between a neuropeptide Y promoter polymorphism and body mass index during the course of development. Pediatr Obes, 2012 showed the genotype-BMI association strengthens during development, with T-allele carriers diverging progressively from CC homozygotes. The POUNDS LOST trial of 723 subjects¹¹¹¹ POUNDS LOST trial of 723 subjects
Qi Q et al. Neuropeptide Y genotype, central obesity, and abdominal fat distribution. Am J Clin Nutr, 2015 demonstrated that rs16147 genotype modifies the effect of dietary fat on abdominal adiposity — T allele carriers gained more visceral fat on high-fat diets.

Migraine and pain. NPY dose-dependently inhibits dural trigeminal neuron firing¹²¹² inhibits dural trigeminal neuron firing
Martins-Oliveira M et al. Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. Pain, 2016 through the Y1 receptor, achieving up to 40% suppression of baseline activity. Lower NPY expression (C allele) could theoretically reduce this endogenous pain-braking mechanism. Changes in NPY levels have been documented in migraine patients, and disruption of the NPY system may explain appetite disturbances commonly reported during migraine attacks.

Blood pressure. The same POUNDS LOST trial¹³¹³ POUNDS LOST trial
Zhang X et al. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure. Hypertension, 2012 found that rs16147 genotype modifies blood pressure response to dietary interventions, with differential effects depending on dietary fat content — highlighting NPY's role in sympathetic cardiovascular regulation.

Practical Implications

This variant presents an unusual trade-off. The T allele confers greater stress resilience and enhanced parasympathetic tone under pressure — but also predisposes to higher appetite drive and central fat accumulation, especially on high-fat diets. The C allele is associated with lower obesity risk but greater vulnerability to anxiety and stress-related conditions when exposed to adversity.

The actionable implications depend on your genotype: C allele carriers benefit from targeted stress-buffering strategies and may want to monitor for anxiety symptoms during stressful periods. T allele carriers should be aware of their heightened appetite drive, particularly for carbohydrates, and may benefit from dietary fat moderation to manage abdominal fat accumulation.

Interactions

NPY and BDNF (rs6265) converge on stress resilience pathways. Both neuropeptides are released in an activity-dependent manner and both modulate the HPA axis stress response. Individuals carrying both the NPY rs16147 CC genotype (lower stress-induced NPY) and the BDNF Met allele (rs6265 CT or TT, reduced activity-dependent BDNF release) may experience compounded vulnerability to stress-related mood disturbance, as both endogenous stress-buffering systems are attenuated simultaneously.

NPY also interacts with the HPA axis through FKBP5 (rs1360780). FKBP5 regulates glucocorticoid receptor sensitivity, and impaired NPY stress-braking combined with enhanced glucocorticoid signaling (rs1360780 T allele) could amplify stress reactivity beyond what either variant produces alone.

The chromosome 5q31 region is one of the most gene-dense immunological hotspots in the human genome, packed with interleukin genes (IL4, IL5, IL13) and other immune regulators across hundreds of kilobases of strong linkage disequilibrium. rs17166496 sits within an intron of FSTL4 (Follistatin-Like 4), a secreted glycoprotein that modulates BMP signaling¹¹ BMP signaling
Bone Morphogenetic Protein signaling; BMP ligands regulate cell differentiation, inflammation, and tissue homeostasis and is predominantly expressed in the brain and central nervous system. The variant was identified in the landmark 2007 WTCCC genome-wide association study as a moderate-evidence signal for type 1 diabetes susceptibility — specifically, one where the heterozygous genotype carries a meaningful protective effect.

The Mechanism

FSTL4 is a member of the follistatin-like protein family, which includes FSTL1, FSTL2 (IGFBP7), FSTL3, FSTL4, and FSTL5. These proteins share structural domains — a Kazal-like domain, follistatin modules, and EF-hand calcium-binding domains — that enable them to bind and inhibit BMP ligands and other TGF-β superfamily members. FSTL1, the most-studied family member, has established roles in immune regulation and cardiac protection. FSTL4 and FSTL5 remain among the least-characterized proteins in the family.

rs17166496 is an intronic variant (NM_015082.2:c.727+19462, intron variant on the coding strand) located deep within FSTL4 and does not alter the amino acid sequence. Its functional mechanism — if any — is presumed to be regulatory: the variant may affect intronic splicing enhancer sequences, alter chromatin accessibility, or modify the expression of FSTL4 or a neighboring gene in immune-relevant tissues. The FSTL4 gene has low but detectable expression in the thymus (1.5 nTPM) and bone marrow (2.2 nTPM), tissues central to T-cell education and immune self-tolerance. However, a causal link between rs17166496 and FSTL4 expression in these tissues has not been established.

The chromosome 5q31 locus has been observed across multiple immune-related GWAS studies with extended linkage disequilibrium making it difficult to isolate the true causal gene. The WTCCC paper²² WTCCC paper
Wellcome Trust Case Control Consortium; Genome-wide association study of 14,000 cases. Nature, 2007 explicitly notes that "the identity of the causative gene is disputed owing to extensive regional linkage disequilibrium" at this locus.

The Evidence

The primary evidence for rs17166496 comes from the 2007 WTCCC genome-wide association study³³ 2007 WTCCC genome-wide association study
Wellcome Trust Case Control Consortium; n=14,000 cases across seven diseases; 3,000 shared controls; Affymetrix 500K array. Nature 447:661-78, 2007, which was the largest GWAS of common diseases at the time and remains one of the most influential studies in human disease genetics. rs17166496 appeared in Table 4 (moderate-evidence associations) for type 1 diabetes (T1D):

• Heterozygous CG genotype: OR = 0.77 (95% CI 0.68–0.87) — a protective effect
• Homozygous CC genotype: OR = 1.09 (95% CI 0.92–1.29) — not significantly different from GG
• Genotypic p-value: 5.20×10⁻⁶ (below GWAS threshold of 5×10⁻⁸)
• Control allele frequency: G=39.1% in British controls

The protective effect is most pronounced in the heterozygous CG state — a pattern suggesting a dominance effect where a single C allele is protective but two C alleles lose this advantage. This non-additive inheritance pattern is biologically unusual and, alongside the sub-threshold p-value and lack of independent replication at genome-wide significance, warrants caution in interpreting the finding.

The WTCCC results should be considered generating rather than confirming evidence. The 5q31 signal has been noted in T1D linkage studies dating back to the 1990s, suggesting biological relevance, but no subsequent study has definitively identified a specific causal gene or variant in this region for T1D at genome-wide confidence. The evidence level for rs17166496 specifically is therefore rated as emerging.

Practical Actions

For people carrying the GC genotype (heterozygous), the data suggest a modestly reduced T1D risk compared to GG homozygotes, consistent with the observed protective odds ratio. This does not translate to a specific supplement, dietary change, or lifestyle intervention — the mechanism is unknown and there is no evidence that external factors modify the genetic effect at this locus.

For GG homozygotes (the genotype with the reference-level T1D risk in the WTCCC data), awareness of family history and standard autoimmune diabetes screening is appropriate, especially if first-degree relatives have T1D. Autoimmune antibody testing (islet cell antibodies, anti-GAD, anti-IA-2) is the established approach for identifying pre-diabetes in genetically at-risk individuals.

Interactions

The 5q31 region sits adjacent to major cytokine genes IL4, IL5, and IL13 — all Th2 immune regulators — and upstream of the IRF1 (interferon regulatory factor 1) gene region. Extended LD means rs17166496 may be tagging a functional variant in any of several neighboring genes rather than a FSTL4-specific effect. Known T1D risk genes such as PTPN22 (rs2476601) on chromosome 1p13 and ERBB3 (rs2292239) on chromosome 12q13 represent independent loci with much stronger and better-replicated associations. rs6596075 is another chromosome 5 variant that has been noted in the same WTCCC study context at 5q31 in a gene-desert region and is in partial LD with rs17166496.